Do you want to read an article? Please log in or register.
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Ann Oncol.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M, PROREPAIR-B investigators., Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E
doi: 10.1016/j.annonc.2020.06.006.
Gastrointestinal Cancer
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
Lancet Oncol
Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling F, Eklund M, Grönberg H, STHLM3 study group.
doi: 10.1016/S1470-2045(21)00348-X
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
SPECIAL REPORT
Gastrointestinal CancerFurther Publications
Why Liquid Biopsy for GI Tumor Treatment Matters
Genitourinary Cancer
Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer
Ann Oncol.
Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK
doi: 10.1016/j.annonc.2020.03.309.
Genitourinary Cancer
Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Klotz L, Chin J, Black PC, Finelli A, Anidjar M, Bladou F, Machado A, Levental M, Ghai S, Chang S, Milot L, Patel C, Kassam Z, Moore C, Kasivisanathan V, Loblaw A, Kebabdjian M, Earle CC, Pond GR, Haider MA
doi: 10.1001/jamaoncol.2020.7589
Genitourinary Cancer
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Eur Urol.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM
doi: 10.1016/j.eururo.2020.04.061.
Genitourinary Cancer
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Lancet Oncol.
Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.
Genitourinary Cancer
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial
JAMA Oncol.
Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung, Krivoshik A, Scher HI, Morris MJ
doi: 10.1001/